On April 29, 2026, NPR reported that the second Trump administration has effectively eliminated U.S. funding for international family planning, contraception, and condom distribution — declining to spend money Congress already appropriated for the work and proposing further cuts in the FY2027 budget. Secretary of State Marco Rubio confirmed the policy at a May 2025 congressional hearing: "There's no plan to spend that money. We're not going to be in that business globally. We're not going to do it."

Why It Matters

USAID was historically the world's largest single funder of contraceptive supplies for low-income countries. Its withdrawal restructures the entire global family planning financing stack — likely shifting demand toward European donors, the Gates Foundation, and private players. For U.S. femtech companies that have benefited from international partnerships and pilots in USAID-supported markets (Natural Cycles, period care brands, at-home STI testing companies), the political environment for cross-border reproductive health work just got materially more hostile. Domestically, the cuts also signal what the administration is likely to do to remaining domestic family-planning programs.

NPR's reporting documented specific eliminated activities including "reproductive health education and access to birth control" in Ghana and "providing condoms and contraception in Kenya." Rural clinics have closed, community health workers and nurse-midwives have been laid off, and technical experts have been pulled from health ministries across multiple recipient countries. The Reproductive Health Supplies Coalition projects a "massive shortfall" in 2026 funding for global contraceptive supply.

The FY2027 budget request, released earlier in April, again zeroes out family planning aid with the line "the United States should not pay for the world's birth control." The cuts come as the U.S. domestic Title X program faces its own funding cliff — combined, the policy posture removes the United States as a primary financier of contraceptive access for tens of millions of people, both at home and abroad.

For the sexual wellness industry, the consequences are downstream but real: condom manufacturers (notably Karex, which makes 20% of the world's condoms and recently warned of 30% price hikes from Iran-war supply disruptions) lose their largest institutional buyer; reproductive health NGOs and femtech startups operating in low-resource markets lose a key partner and reference customer; and demand for at-home and long-acting contraceptive products in affected regions will increasingly fall on private and DTC channels.

Sources

Update — 2026-04-30

Initial entry — story first created.